References
- Furie B, Greene E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X. N Engl J Med 1977;297:81–85.
- Coppola A, Tufano A, Di Capua M, et al. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 2011;37:929–945.
- Eng AS. Pathogenesis of myeloma neuropathy through sharing epitopes with myelin basic protein [Letter]. Lancet 1983; 2(8353): 801.
- Cokonis Georgakis CD, Falasca G, Georgakis A, et al. Scleromyxedema. Clin Dermatol 2006;24:493–497.
- Dispenzieri A. POEMS syndrome. Blood Rev 2007;21:285–299.
- Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014;15:333–342.
- Engelhardt M, Ihorst G, Landgren O, et al. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. Haematologica 2015;100:1340–1349.
- Kohmura K, Miyakawa Y, Kameyama K, et al. Granulocyte colony stimulating factor-producing multiple myeloma associated with neutrophilia. Leuk Lymphoma 2004;45:1475–1479.
- Cehreli C, Undar B, Akkoc N, et al. Coexistence of chronic neutrophilic leukemia with light chain myeloma. Acta Haematol 1994;91:32–34.
- Taiwo E, Wang H, Lewis R. Treatment of coexisting chronic neutrophilic leukemia and light chain multiple myeloma with hydroxyurea, bortezomib, and dexamethasone. Case Rep Hematol 2014;2014:869395.
- Stevens B, Maxson J, Tyner J, et al. Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. Leuk Lymphoma 2016;57:928–935.
- Tefferi A, Elliott M, Pardanani A. Chronic neurophilic leukemia: novel mutations and their impact on clinical practice. Curr Opin Hematol 2015;22:171–176.